Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)

TYO:2395 Financials Overview

Financials in millions JPY. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	33,916	32,524	32,413	26,450	25,090	17,748
Revenue Growth	1.72%	0.34%	22.54%	5.42%	41.37%	17.46%
Gross Profit Gross Profit Growth	15,217	16,237	16,960	14,282	13,046	9,687
Operating Income Operating Income Growth	3,517	2,653	2,985	4,162	5,245	4,196
Net Income Net Income Growth	5,370	4,566	4,924	5,531	6,060	7,127
Earnings Per Share EPS Growth	129.00	109.68	118.28	132.86	145.56	171.19
EPS Growth	6.07%	-7.27%	-10.97%	-8.73%	-14.97%	94.67%

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Medipolis Business Medipolis Business Growth	831.3	804.31	564.93	569.08	683.66	563.5
Other Other Growth	1,925	1,965	1,790	1,407	1,437	968.97
US Property Management Business US Property Management Business Growth	190.33	184.4	45.98	-	-	-
Unallocated Adjustments Unallocated Adjustments Growth	-1,783	-1,815	-1,637	-1,449	-1,047	-844.7
Translational Research Business Translational Research Business Growth	120.87	108.2	54.16	13.23	16.48	12.86
CRO Business CRO Business Growth	32,632	31,277	31,595	25,910	24,000	17,048
Total Total Growth	33,916	32,525	32,414	26,450	25,091	17,748

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	14,334	18,536	12,032	10,610	10,533	6,996
Total Debt Total Debt Growth	37,584	41,258	34,473	26,185	18,760	9,136
Net Cash (Debt) Net Cash Growth	-23,249	-22,722	-22,441	-15,575	-8,227	-2,140
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share Net Cash Per Share Growth	-558.45	-545.80	-539.05	-374.12	-197.62	-51.40

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	-	8,327	7,035	2,106	4,004	5,952
Capital Expenditures CapEx Growth	-	-5,173	-10,853	-8,582	-4,838	-1,542
Free Cash Flow Free Cash Flow Growth	-	3,154	-3,818	-6,476	-834	4,410
Free Cash Flow Growth	-	-	-	-	-	19.87%

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	44.87%	49.92%	52.33%	54.00%	52.00%	54.58%
Operating Margin	10.37%	8.16%	9.21%	15.73%	20.91%	23.64%
Pretax Margin	21.59%	19.21%	18.55%	26.37%	30.92%	46.10%
Profit Margin	15.83%	14.04%	15.19%	20.91%	24.15%	40.16%
FCF Margin	-	9.70%	-11.78%	-24.48%	-3.32%	24.85%

Dividends

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 12, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Dividend Per Share Dividend Per Share Growth	50.000	50.000	50.000	50.000	50.000	30.000
Dividend Per Share Growth	0%	0%	0%	0%	66.67%	200.00%
Dividend Yield	3.36%	3.54%	3.61%	3.53%	2.01%	1.99%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 12, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	11.53	12.89	12.10	11.43	18.89	9.91
Forward PE	15.61	12.72	11.02	12.72	17.36	13.68
P/FCF Ratio	19.63	18.66	-	-	-	16.01
PS Ratio	1.83	1.81	1.84	2.39	4.56	3.98

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 11, 2026

Data Sources Report a data error